Possible radiation-induced dural fibrosarcoma with an unusually short latent period: case report.

Neurosurgery

Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.

Published: March 1995

We report a case of radiation-induced dural fibrosarcoma in a 9.5-year-old male patient who was treated with radiation for medulloblastoma. He received a total dose of 53.2-Gy radiation, delivered at 1.6 and 1.8 Gy per fraction with a 6 MV linear accelerator using the standard cranial-spinal technique. A sequential magnetic resonance image at 15 months after the completion of radiation therapy showed a mass above the cerebral convexity that increased two-fold in size within a period of 4 months. The tumor showed characteristics of a low-grade fibrosarcoma. This case emphasizes the potential risk of early development of a second neoplasm after therapeutic radiation, especially in children, and also documents what is to our knowledge the shortest latent period between the administration of radiation therapy and the development of an intracranial fibrosarcoma that has been reported.

Download full-text PDF

Source
http://dx.doi.org/10.1227/00006123-199503000-00021DOI Listing

Publication Analysis

Top Keywords

radiation-induced dural
8
dural fibrosarcoma
8
latent period
8
radiation therapy
8
radiation
5
fibrosarcoma
4
fibrosarcoma unusually
4
unusually short
4
short latent
4
period case
4

Similar Publications

Background And Objective: Radiosurgery can serve as a primary, adjuvant, or salvage treatment modality for cavernous sinus tumors (CST), providing high tumor control. However, particularly with cavernous sinus expansion, there may be insufficient distance from the optic apparatus to perform radiosurgery safely. The internal carotid artery adjacent to the distal dural ring (ICAddr), when enhancing similarly to the CST, can be difficult to delineate, and can lead to over-contouring of target volume near the optic nerve and therefore increasing the risk of radiation-induced optic toxicity.

View Article and Find Full Text PDF
Article Synopsis
  • * The girl experienced a rapid decline after surgery, ultimately resulting in life-threatening infarcts due to MMS, highlighting the need for timely diagnosis of this condition post-radiotherapy.
  • * To mitigate risks during treatment for tumor recurrence, medical management and revascularization are key, along with a recommendation for a trans-nasal surgical approach to preserve blood flow from existing collaterals.
View Article and Find Full Text PDF

Objective: The role of stereotactic radiosurgery (SRS) in the management of intracranial dural arteriovenous fistula (dAVF) is unclear given the rarity of this lesion and the variability in treatment paradigms. This study describes a 3-decade experience with the SRS technique and its outcomes for patients with dAVF.

Methods: The authors conducted a retrospective analysis of patients with dAVF who had undergone single-fraction SRS in the period from 1990 to 2021.

View Article and Find Full Text PDF

Background And Objectives: Hemangiopericytomas are infrequent vascular tumors originating from Zimmermann pericytes. The conventional treatment involves gross total resection, followed by adjuvant radiotherapy. Nevertheless, their tendency to infiltrate dural sinuses, high vascularity, and anatomic complexity pose challenges for radical resection, leading to a significant risk of recurrence.

View Article and Find Full Text PDF

Paediatric patients receiving cranial irradiation therapy for brain tumours are at increased risk of cerebrovascular complications. Radiation-induced moyamoya syndrome (MMS) is a well-recognised complication of this. We present a case of an 8-year-old boy with a history of medulloblastoma, who underwent surgical excision followed by post-operative adjuvant oncological treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!